← Eichor
Study identifier: NCT07014410 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer

Condition: Breast Cancer  ·  Sponsor: Zhejiang Cancer Hospital

PhasePhase 2
Planned participants63
Who can joinFemale, 18 Years to 75 Years
Healthy volunteersNo

About this study

This is a a multicenter Phase II clinical study investigating efficacy of pyrotinib combined with dalpiciclib combined with letrozole in ER-positive and HER2-positive advanced breast cancer patients. The sample size is 63.

This description comes directly from the study's public registry record.

Talk to the study team

Zhiqiang Xiao, Master  ·  17757194561  ·  zhiqiang.xiao@hengrui.com

Zhiqiang Xiao  ·  17757194561  ·  zhiqiang.xiao@hengrui.com

Always discuss trial participation with your own doctor first.

Locations (1)

Zhejiang Cancer HospitalHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07014410